Which Weight Management Injection Suits Your Lifestyle?
Wegovy or Saxenda vs Mounjaro: Understanding the Key Differences
When comparing Wegovy or Saxenda against Mounjaro, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormones, whilst Saxenda uses liraglutide, also a GLP-1 agonist but with daily dosing requirements. Mounjaro stands apart as tirzepatide, the first dual GIP and GLP-1 receptor agonist, targeting two separate hormone pathways simultaneously.
The dosing schedules create practical differences for patients considering Wegovy or Saxenda versus Mounjaro. Wegovy requires once-weekly injections starting at 0.25mg and escalating to 2.4mg maintenance, whilst Saxenda demands daily injections beginning at 0.6mg daily. Mounjaro follows a weekly schedule like Wegovy, starting at 2.5mg and potentially reaching 15mg at maintenance. Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber to determine which weekly option aligns with your lifestyle preferences.
Wegovy or Saxenda Pricing vs Mounjaro: Complete Cost Analysis
EverydayMeds offers transparent pricing for patients weighing Wegovy or Saxenda against Mounjaro options. Wegovy pricing begins with our 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to maintenance 2.4mg at £209.99. New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices. Our Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, offering convenience through fewer orders and Reliable Supply.
When evaluating Wegovy or Saxenda versus Mounjaro costs, consider the different dose escalation timelines affect total treatment expenses. Wegovy requires 16 weeks to reach maintenance dosing, whilst Mounjaro's escalation varies based on individual tolerance and prescriber guidance. Both treatments are prescription-only medicines requiring ongoing clinical supervision, making our GPhC-registered pharmacy service (#9012878) essential for safe, legal access to these regulated medications.
Clinical Evidence: Wegovy or Saxenda vs Mounjaro Trial Data
In clinical trials, patients taking Wegovy alongside diet and exercise achieved significant weight management outcomes, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. The STEP 2 trial showed clinically studied weight loss in patients with type 2 diabetes, whilst STEP 3 achieved 16% with intensive behavioural therapy support. Importantly, the SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events for Wegovy patients.
Patients considering Wegovy or Saxenda versus Mounjaro should understand that direct head-to-head comparison trials have not been conducted between these treatments. Each medication demonstrated efficacy in separate clinical programmes with different trial designs, patient populations, and endpoints, as referenced in Wilding et al., NEJM, 2021 for Wegovy's pivotal studies. Your prescriber can review individual clinical evidence to determine which option may be most suitable for your specific health profile.
How Wegovy Works: GLP-1 Mechanism for Appetite Control
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a hormone naturally produced in your intestine after eating. When you inject Wegovy subcutaneously once weekly, it binds to GLP-1 receptors in your brain's appetite centres, particularly the hypothalamus, reducing hunger signals and food cravings. The medication simultaneously slows gastric emptying, meaning food remains in your stomach longer, promoting sustained feelings of fullness after smaller meals. This dual mechanism—central appetite suppression and peripheral satiety enhancement—supports portion control when combined with a reduced-calorie diet and increased physical activity. Clinical studies suggest Wegovy may also influence reward pathways associated with food, potentially reducing cravings for high-calorie, palatable foods that often undermine weight management efforts.
Ordering Process: From Assessment to Delivery
EverydayMeds streamlines access to Wegovy or Saxenda and Mounjaro through our comprehensive online service designed for UK patients. Begin with our 3-minute clinical assessment covering your medical history, current medications, weight management goals, and any relevant health conditions that might influence treatment selection. Our qualified prescribers review your assessment within standard 3 working days, or choose express review within 24 hours for faster processing. Once approved, your prescription-only medicine ships via next-day delivery using our temperature-controlled cold-chain logistics, ensuring medication integrity from our GPhC-registered pharmacy (#9012878) directly to your door. Each delivery includes detailed injection technique guidance, dose escalation schedule, and direct access to our clinical support team for ongoing questions throughout your treatment journey.
Storage Requirements: Wegovy or Saxenda vs Mounjaro Practicalities
Storage differences between Wegovy or Saxenda and Mounjaro create practical considerations for patients with active lifestyles or frequent travel requirements. Wegovy pens must be stored in your refrigerator at 2-8°C before first use, but offer exceptional flexibility once removed—maintaining potency for up to 6 weeks at room temperature below 30°C. This storage advantage significantly exceeds Mounjaro's 21-day room temperature limit, making Wegovy particularly suitable for extended travel, business trips, or situations where refrigeration access might be intermittent. Each Wegovy pen uses Novo Nordisk's FlexTouch delivery system, pre-filled with your prescribed dose and requiring no mixing or preparation before injection.
Choosing Between Wegovy or Saxenda and Mounjaro: Decision Factors
Patients evaluating Wegovy or Saxenda versus Mounjaro should consider several practical factors beyond clinical efficacy. Injection frequency represents a primary consideration—Wegovy offers weekly convenience compared to Saxenda's daily requirement, whilst Mounjaro also follows a weekly schedule. The dose escalation timeline differs significantly, with Wegovy following a structured 16-week progression to maintenance, allowing gradual tolerance development and side effect minimisation.
Individual response variability means some patients may find better tolerability or efficacy with one treatment over another, making prescriber guidance essential in choosing between these options. EverydayMeds stocks both Wegovy and Mounjaro, providing flexibility should your prescriber recommend switching treatments based on your response or changing clinical needs. Both medications require identical lifestyle modifications—reduced-calorie diet and increased physical activity—making them equally suitable for patients committed to comprehensive weight management approaches.
Start Your Weight Management Journey: Expert Prescriber Support
EverydayMeds combines clinical expertise with convenient access, offering both Wegovy and Mounjaro through our regulated online pharmacy service. New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to access our competitive pricing structure starting from £79.99 for Wegovy's initial dose. Our clinical team, operating under GPhC registration #9012878, provides ongoing support throughout your treatment journey, from initial assessment through maintenance dosing adjustments. Whether you choose Wegovy's proven GLP-1 mechanism or Mounjaro's innovative dual-receptor approach, you'll receive the same high-standard clinical oversight and convenient home delivery service. Visit our weight loss collection at https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discover which prescription-only medicine aligns with your individual health goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
